DMT
Disease Modifying Therapies
Tuesday, October 26, 2021: 2:45 PM-4:45 PM
Gatlin A3/A4 (Rosen Shingle Creek)
2:45 PM
Design of the Phase II, Double-Blind, Placebo-Controlled Dose-Expansion Portion of a Two-Part, Phase I/II, Multicenter Trial in Progressive Multiple Sclerosis
Amit Bar-Or, MD, Department of Neurology, Perelman School of Medicine, University of Pennsylvania;
Laurence Gamelin, MD, PhD, Atara Biotherapuetics;
Wei Ye, PhD, Atara Biotherapuetics;
Jonathan Willmer, MD, Atara Biotherapuetics;
Blake T Aftab, PhD, Atara Biotherapuetics;
Michael P Pender, MD, PhD, The University of Queensland
3:00 PM
Postpartum Relapse Rates in Women with Relapsing Multiple Sclerosis and the Impact of Disease-Modifying Drugs: A Systematic Review
Kerstin Hellwig, MD, PhD, St. Joseph and St. Elisabeth Hospital, Ruhr University;
Elisabetta Verdun di Cantogno, MD, PhD, Merck KGaA;
Meritxell Sabidó, MD, PhD, Merck KGaA
3:15 PM
Improvements in Work Productivity and Activity Impairment in Ocrelizumab-Treated Patients with RRMS: 2-Year Data from the CASTING Study
Giancalo Comi, PhD, Vita-Salute San Raffaele University;
Gary Cutter, PhD, University of Alabama at Birmingham;
Ilya Kister, MD, Multiple Sclerosis Comprehensive Care Center;
Bart van Wijmeersch, MD, PhD, University MS Centre, Pelt, Hasselt University;
Regine Buffels, MD, F. Hoffmann-La Roche Ltd;
Thomas Kuenzel, PhD, F. Hoffmann-La Roche Ltd;
Yekaterina Poloz, PhD, F. Hoffman-La Roche Ltd;
Patrick Vermersch, PhD, University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Imminent
3:30 PM
Efficacy and Safety of Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 Ultimate I and II Trials
Lawrence Steinman, MD, Stanford University School of Medicine;
Edward J. Fox, MD, PhD, Central Texas Neurology Consultants and Dell Medical School, The University of Texas at Austin;
Hans-Peter Hartung, M.D., Heinrich Heine University;
Enrique Alvarez, MD, PhD, University of Colorado School of Medicine;
Peiqing Qian, MD, Swedish Neuroscience Institute;
Sibyl Wray, MD, Hope Neurology;
Derrick Robertson, MD, University of South Florida, Morsani College of Medicine;
DeRun Huang, MD, PhD, MDH Research;
Krysztof Selmaj, MD, PhD, Medical Academy of Lodz;
Daniel Wynn, MD, Consultants in Neurology MS Center;
Michael S Weiss, J.D., TG Therapeutics;
Jenna Bosco, BA, TG Therapeutics;
Sean Power, BA, TG Therapeutics;
Koby Mok, PhD, TG Therapeutics;
Bruce A.C. Cree, MD, PhD, MAS, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco
3:45 PM
Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: Artios Phase 3b Study Design
Matthew Craner, MB ChB FRCP PhD, John Radcliffe Hospital, Oxford University Hospitals NHS Trust;
Riley Bove, MD, University of California San Francisco;
Dawn Langdon, PhD, Royal Holloway, University of London;
Daniel Detka, PhD, Novartis Pharma AG;
Javier Ricart, PhD, Novartis Farmacéutica;
Alomi Mistry, MS, Novartis Healthcare Pvt. Ltd.;
Patricia Maxwell, BS, Novartis Pharmaceuticals Corporation;
Chaitali Babanra Pisal, MS, Novartis Healthcare Pvt. Ltd.;
Pruthvi Desireddy, MD, Novartis Healthcare Pvt. Ltd.;
Dee Stoneman, MPharm, Novartis Pharma AG;
Marina Ziehn, PhD, Novartis Pharma AG;
Tobias Derfuss, MD, Departments of Medicine and Biomedicine, University Hospital and University of Basel
4:00 PM
COVID-19 Vaccine Response in People with MS Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy
Matthew A Tremblay, MD, Ph.D, RWJ Barnabas Health;
Andrew Sylvester, MD, RWJ Barnabas Health;
Mary Yarussi, BSN, RWJ Barnabas Health;
Phoebe Del Boccio, PhD, RWJ Barnabas Health;
Meera Patel, BS, RWJ Barnabas Health;
J Tamar Kalina, PhD, Biogen;
Jason P. Mendoza, PhD, Biogen;
Robin Avila, PhD, Biogen
4:15 PM
Recently Diagnosed Early-Stage RRMS: Neda, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data from the Ocrelizumab Phase IIIb ENSEMBLE Study
Timothy Vollmer, MD, Department of Neurology, University of Colorado School of Medicine;
Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC, University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute;
Joep Killestein, MD, PhD, Department of Neurology, VU University Medical Center;
Carlos Nos, MD, Vall d’Hebron Hospital Universitari, 08035;
Ludo Vanopdenbosch, MD, AZ Sint-Jan Brugge-Oostende;
Regine Buffels, MD, F. Hoffmann-La Roche Ltd;
Karen Kadner, MD, PhD, F. Hoffmann-La Roche Ltd;
Thomas Kuenzel, PhD, F. Hoffmann-La Roche Ltd;
Hans-Peter Hartung, M.D., Heinrich-Heine-University Düsseldorf
